Lineage Cell Therapeutics, Inc. (LCTX)

Market Cap	156.65M
Revenue (ttm)	9.56M
Net Income (ttm)	-16.21M
Shares Out	228.36M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	737,130
Open	0.6548
Previous Close	0.6523
Day's Range	0.6400 - 0.6950
52-Week Range	0.3651 - 1.1500
Beta	1.42
Analysts	Strong Buy
Price Target	4.20 (+512.25%)
Earnings Date	May 13, 2025

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 77
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: LCTX
• Website: https://www.lineagecell.com

Financial Performance

In 2024, Lineage Cell Therapeutics's revenue was $9.50 million, an increase of 6.19% compared to the previous year's $8.95 million. Losses were -$18.61 million, -13.39% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for LCTX stock is "Strong Buy." The 12-month stock price forecast is $4.2, which is an increase of 512.25% from the latest price.

Price Target

$4.2

(512.25% upside)

Analyst Consensus: Strong Buy